Table I.
Characteristics of the included studies.
| Intervention measures | ||||||||
|---|---|---|---|---|---|---|---|---|
| Author, year | Number of samples (T/C) | T | C | Number of injected cells | Transplant time after modeling (days) | Outcome time (days) | Outcome indicator | (Refs.) |
| Yang et al, 2016 | 30/15 | BLM+BMSCs | BLM+saline | 0.2×107 | 1,14 | 7,14,28 | a,b | (31) |
| Cui et al, 2007 | 16/16 | BLM+BMSCs | BLM+PBS | 2.5×106 | 1,7 | 28 | a,b | (32) |
| Huang et al, 2012 | 18/18 | BLM+BMSCs | BLM+saline | 2.5×106 | 1 | 7,14,28 | a,b | (33) |
| Wang et al, 2014 | 24/12 | BLM+BMSCs | BLM+saline | 1×106 | 1,14 | 28 | a,b | (34) |
| Wang et al, 2009 | 28/21 | BLM+BMSCs | None | 5 ml/kg | 1,14 | 7,14,28 | a,b | (35) |
| Zeng et al, 2016 | 15/15 | BLM+BMSCs | BLM+saline | 5×105 | 1 | 7,14,21 | a,b | (36) |
In all studies, BMSCs were administered via tail vein injection. T, treatment group; C, control group; BMSCs, bone marrow mesenchymal stem cells; BLM, bleomycin; d, day; a, alveolitis; b, pulmonary fibrosis.